Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut - Tập 61 Số 12 - Trang 1693-1700 - 2012
Wolfgang Hueber1, Bruce E. Sands2, Steve Lewitzky3, Marc Vandemeulebroecke1, Walter Fries4, Peter Higgins5, Jan Wehkamp6, Brian G. Feagan7, Michael Yao8, Marek Karczewski9, Jakub Karczewski9, Nicole Pezous1, Stephan Bek1, Gerard Bruin1, Bjoern Mellgard1, C Berger1, Marco Londei10, Arthur P. Bertolino1, Gervais Tougas1, Simon Travis11
1#N##TAB##TAB##TAB##TAB# Novartis#N##TAB##TAB##TAB#
2Icahn School of Medicine at Mount Sinai (ISMMS)
3Novartis, USA
4#N##TAB##TAB##TAB##TAB# Medical University of Vienna#N##TAB##TAB##TAB#
5Internal Medicine - Gastroenterology
6Robert-Bosch-Krankenhaus, Stuttgart
7Western University
8National Institutes of Health, Bethesda
9Solumed Research Unit
10Novartis Research Foundation
11University of Oxford.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Gut

Tập 61 Số 12

1693-1700

Thông tin tác giả